Efficacy and Safety of Dihydroartemisinin/Piperaquine (Artekin®) for the Treatment of Uncomplicated Malaria in PeruSafety Study on the Effect of Eurartesim™ on QT/QTc Interval Compared to Riamet in Healthy VolunteersDihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in SudanMalaria in Early Life StudyA Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum MalariaTreatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy (TRANSACT)Safety, Tolerability and Antimalarial Activity of Single Doses of OZ439 and PQPTracking Resistance to Artemisinin (TRAC)Efficacy of Artemether-lumefantrine, Artesunate-amodiaquine and Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in MalawiSchool Based Malaria Control in Ugandan SchoolchildrenEfficacy,Safety and Tolerability of Dihydroartemisinin-Piperaquine for Uncomplicated Malaria in Pregnancy in GhanaMass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria EliminationControlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan ChildrenEfficacy and Safety of ASAQ and PD for the Treatment of Uncomplicated Falciparum Malaria in Mainland TanzaniaTriple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant ParasitesImproving Maternal heAlth by Reducing Malaria in African HIV WomenEvaluation of the Implementation and Effectiveness of Intermittent Preventive Treatment for Malaria Using Dihydroartemisinin-piperaquine on Reducing Malaria Burden in School Aged Children in TanzaniaControlled Human Malaria Infection Transmission Model - Phase AOptimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda
P4844
Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malariaeditAntimalarial efficacy of piperaquine-based antimalarial combination therapies: facts and uncertaintiesMetabolite identification of the antimalarial piperaquine in vivo using liquid chromatography-high-resolution mass spectrometry in combination with multiple data-mining tools in tandem.Fixed dose combination of arterolane and piperaquine: a newer prospect in antimalarial therapyPiperaquine: a resurgent antimalarial drug.Progress in the development of piperaquine combinations for the treatment of malaria.Sensitivity of Plasmodium falciparum to antimalarial drugs in Hainan Island, China.Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations.Quantification of the antimalarial piperaquine in plasma.Development and validation of an LC-MS/MS method for simultaneous determination of piperaquine and 97-63, the active metabolite of CDRI 97-78, in rat plasma and its application in interaction study.Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam
P921
Q61932743-E4AAE5AF-1688-4059-B9A5-0E1F2B22B663Q61935753-634EF8F4-DE36-40CD-9A92-538656079E0BQ61938184-00D22285-22C5-451C-87D1-2074609988A3Q61969210-3973BFF6-480C-47DD-A95E-AE15D2969C03Q61969902-ADF1BCDC-8D33-4F5B-A8A8-B41F944A0F91Q61980691-01D62CCC-28B6-4F9E-B161-9BBAF1AA412EQ62811534-67AB2181-B03C-4C98-863E-DC74A9A68BE2Q63334695-79A9254A-2ACF-4728-8AC0-640B44CF32EDQ63338889-34F3E281-F71D-4BBD-AFEA-5EFCB5AF480AQ63341048-E2DFC51F-3FE5-42E7-B662-F3B5129E28E9Q63341110-2FA1E50A-A2B3-4F7F-BE0D-AACAF8AE7A0DQ63396158-BE68A52E-AD56-471B-B772-059E85FF33D5Q63400554-65C70BB0-4A5A-43A8-A998-5C64D03D670FQ63400696-D9B081ED-A65C-41F1-ADC1-BFC8CE2B4763Q63403905-4FF48DA3-94B6-43C8-A144-42A79A60AD51Q63597942-B51E50CC-DD03-4500-87EB-DE02A183B920Q63598635-7C6D0C51-6207-4D5B-A5FF-92859299C106Q86257556-1520E8B9-3AF1-4241-B0FA-A25E2DA70E15Q87930231-B78F92EF-DAE0-44B0-8393-083010CC4A4FQ90693609-120C24B4-1509-472F-8C88-B41F4BE58313
P4844
Q21032449-193A8E8C-FB9E-40B8-9A63-06AE318ED260Q26866187-8C3AA734-59C7-4086-B68F-DADB5B5C4D74Q31040806-DDB9B261-A60C-4337-8287-30627967090EQ34162314-58414A40-6D36-40A9-A2F5-08D601B66448Q34378146-E74C289B-5B21-473A-9C39-AB4C9A1F528BQ35004620-AE963B76-5D13-4F16-95B6-607B09DA021FQ35262245-AB453798-5232-489B-81A5-A293869B7105Q35875707-B05CBC51-6D4B-469B-9FE0-90300B7419F9Q37123993-491B3FD7-A6E8-4AFD-AEBC-A675A75C7974Q47914315-2C538C7A-0AE3-4C8F-99E9-71E5256F02D2Q61446945-E31F0514-821C-4C55-BA09-6D8A5A37AEF3
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Piperachină
@ro
Piperakiini
@fi
Piperakuin
@id
Piperakvin
@sh
Piperakvin
@sr
Piperaquine
@vi
piperaquine
@en
喹哌
@zh
type
label
Piperachină
@ro
Piperakiini
@fi
Piperakuin
@id
Piperakvin
@sh
Piperakvin
@sr
Piperaquine
@vi
piperaquine
@en
喹哌
@zh
altLabel
1,3-bis[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propane
@en
Piperaquine
@en
piperaquinoline
@en
prefLabel
Piperachină
@ro
Piperakiini
@fi
Piperakuin
@id
Piperakvin
@sh
Piperakvin
@sr
Piperaquine
@vi
piperaquine
@en
喹哌
@zh
P486
P592
P6366
P661
P662
P683
P117
P1579
P2067
P231
P233
C1CN(CCN1CCCN2CCN(CC2)C3=C4C=CC(=CC4=NC=C3)Cl)C5=C6C=CC(=CC6=NC=C5)Cl
P234
1S/C29H32Cl2N6/c30-22-2-4-24-2 ...... 25(27)29/h2-9,20-21H,1,10-19H2
P235
UCRHFBCYFMIWHC-UHFFFAOYSA-N
P274
C₂₉H₃₂Cl₂N₆
P2868
P3117
DTXSID00193825
P486
P592
CHEMBL303933
P6366
2777616469
P652
A0HV2Q956Y